ANAVAR - 90 tablets x 10mg by Euro Generic Pharm Ltd


ANAVAR - 90 tablets x 10mg by Euro Generic Pharm Ltd

In stock

Be the first to review this product


original products
free shipping over 50€


Before use please read this leaflet carefully!

Active ingredients:Oxandrolone

Pharmacological category:Anabolic steroid

Delivery:1pack 90 tablets 10mg

Composition:Each tablet contains 10 mg of Oxandrolone

Clinical pharmacology:
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class
of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are therefore similar to those of
male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children. Anabolic steroids suppress
the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous
testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback
inhibition of pituitary follicle-stimulating hormone (FSH). Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density
lipoproteins. These levels revert to normal on discontinuation of treatment. In a single dose pharmacokinetic study of oxandrolone in elderly subjects, the mean
elimination half-life was 13.3 hours. In a previous single dose pharmacokinetic study in younger volunteers, the mean elimination half-life was 10.4 hours.

Oxandrolone Tablets, USP are indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe
trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated
with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis.

Known or suspected carcinoma of the prostrate or the male breast. Carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate
osteolytic bone resorption).Pregnancy, because of possible masculinization of the fetus. Oxandrolone has been shown to cause embryotoxicity, fetotoxicity, infertility,
and masculinization of female offspring when given in doses 9 times the human dose. Nephrosis, the nephrotic phase of nephritis. Hypercalcemia.

Concurrent dosing of oxandrolone and warfarin may result in unexpectedly large increases

in the International Normalized Ratio (INR) or prothrombin time (PT). When oxandrolone is prescribed to patients being treated with warfarin, doses of warfarin may need
to be decreased significantly to maintain the desirable INR level and diminish the risk of potentially serious bleeding

Drug interactions:
Anticoagulants: Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be decreased in order to maintain desired
prothrombin time. Patients receiving oral anticoagulant therapy require close monitoring,especially when anabolic steroids are started or stopped.
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin
half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng • hr/mL; similar increases in R-warfarin half-life and AUC were also detected. Microscopic hematuria (9/15)
and gingival bleeding (1/15) were also observed. A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of
warfarin dose), was necessary to maintain a target INR of 1.5. When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or
prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.
Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the
oxandrolone dose is changed or discontinued. Patients should be closely monitored for signs and symptoms of occult bleeding.Oxandrolone may inhibit the metabolism
of oral hypoglycemic agents.In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.

Therapy with anabolic steroids is adjunctive to and not a replacement for conventional therapy. The duration of therapy with Oxandrolone Tablets, USP will depend on the
response of the patient and the possible appearance of adverse reactions. Therapy should be intermittent.

The response of individuals to anabolic steroids varies. The daily adult dosage is 2.5 mg to 20 mg given in 2 to 4 divided doses. The desired response may be achieved with
as little as 2.5 mg or as much as 20 mg daily. A course of therapy of 2 to 4 weeks is usually adequate. This may be repeated intermittently as indicated.

Store in a dark, dry place, at room temperature. Do not refrigerate. Keep out of reach of children.

Manufactured by: Euro Generic Pharm Ltd.

This medicine must be given only by medical prescription!

Tablets are blue and EGP stamped.